Geron Corporation Reports Third Quarter 2016 Financial Results and Recent Events
November 03, 2016 16:05 ET
|
Geron Corporation
MENLO PARK, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today reported financial results for the three and nine months ended September 30, 2016 and recent events. For...
Geron Provides Update on Imetelstat Trials Being Conducted by Janssen
September 12, 2016 07:30 ET
|
Geron Corporation
MENLO PARK, Calif., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today provided updates on the clinical trials being conducted by Janssen Research & Development, LLC, of...
Geron Announces December Conference Presentation Webcasts
November 30, 2015 07:30 ET
|
Geron Corporation
MENLO PARK, Calif., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present...
Geron Announces Initiation of Janssen Phase 2 Clinical Trial of Imetelstat in Myelofibrosis
September 16, 2015 07:30 ET
|
Geron Corporation
MENLO PARK, Calif., Sept. 16, 2015 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced the dosing of the first patient in a Phase 2 clinical trial to evaluate imetelstat in...
Infinity Expands Clinical Development Program for IPI-926, an Oral Smoothened Antagonist Targeting the Hedgehog Pathway
June 22, 2011 08:00 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 22, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that it is expanding its clinical development program for IPI-926, a novel, oral small...